Fig. 6: Risankizumab disrupts the persistence of CD8+ TRM cells through interference with the IL-7 and IL-15 signaling. | Nature Communications

Fig. 6: Risankizumab disrupts the persistence of CD8+ TRM cells through interference with the IL-7 and IL-15 signaling.

From: A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab

Fig. 6: Risankizumab disrupts the persistence of CD8+ TRM cells through interference with the IL-7 and IL-15 signaling.

a, b Ligand–receptor interaction probabilities among keratinocyte subtypes and CD8 + TRM1 or CD8 + TRM17 in 300 mg and 600 mg groups. c, d Ligand–receptor interaction probabilities among keratinocyte subtypes and CD8 + TRM1 or CD8 + TRM17 in baseline and 600 mg group. a–d The means of the average expression levels of two interacting molecules are indicated by the color heatmap (bottom panel), with blue to red representing low to high expression. P values were obtained via one-sided permutation tests and are indicated by the circle size. See Supplementary Data for exact P value. e, f Feature plots showing down-regulation of IL7, IL15, and TNFSF15 in keratinocytes.

Back to article page